These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34780372)

  • 1. Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients.
    Younas S; Mukhtar H; Gohar UF; Alsrhani A; Alzahrani B; Junaid K; Qamar MU; Ejaz H
    J Infect Dev Ctries; 2021 Oct; 15(10):1489-1496. PubMed ID: 34780372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.
    Smirne C; D'Avolio A; Bellan M; Gualerzi A; Crobu MG; Pirisi M
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00811. PubMed ID: 34152088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
    Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
    Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
    Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
    Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
    BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
    Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
    Indian J Gastroenterol; 2018 Nov; 37(6):520-525. PubMed ID: 30637537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.
    Hassanien KS; El-Sayed EM; Ismail RS; Zakarya ZM; Helal GK
    J Clin Pharm Ther; 2021 Aug; 46(4):942-949. PubMed ID: 33768560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication.
    Huang CF; Dai CY; Yeh ML; Huang CI; Lee HC; Lai WT; Liang PC; Lin YH; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Huang JF; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2020 Nov; 36(11):920-928. PubMed ID: 32643842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
    Kowdley KV; Nelson DR; Lalezari JP; Box T; Gitlin N; Poleynard G; Rabinovitz M; Ravendhran N; Sheikh AM; Siddique A; Bhore R; Noviello S; Rana K
    Liver Int; 2016 Nov; 36(11):1611-1618. PubMed ID: 27188960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
    Sulkowski MS; Feld JJ; Lawitz E; Felizarta F; Corregidor AM; Khalid O; Ghalib R; Smith WB; Van Eygen V; Luo D; Vijgen L; Gamil M; Kakuda TN; Ouwerkerk-Mahadevan S; Van Remoortere P; Beumont M
    J Viral Hepat; 2018 Jun; 25(6):631-639. PubMed ID: 29274193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
    Sulkowski MS; Gardiner DF; Rodriguez-Torres M; Reddy KR; Hassanein T; Jacobson I; Lawitz E; Lok AS; Hinestrosa F; Thuluvath PJ; Schwartz H; Nelson DR; Everson GT; Eley T; Wind-Rotolo M; Huang SP; Gao M; Hernandez D; McPhee F; Sherman D; Hindes R; Symonds W; Pasquinelli C; Grasela DM;
    N Engl J Med; 2014 Jan; 370(3):211-21. PubMed ID: 24428467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.
    Fourati S; Guedj J; Chevaliez S; Nguyen THT; Roudot-Thoraval F; Ruiz I; Soulier A; Scoazec G; Varaut A; Poiteau L; Francois M; Mallat A; Hézode C; Pawlotsky JM
    Aliment Pharmacol Ther; 2018 Mar; 47(5):665-673. PubMed ID: 29271114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
    Luetkemeyer AF; McDonald C; Ramgopal M; Noviello S; Bhore R; Ackerman P
    Clin Infect Dis; 2016 Jun; 62(12):1489-96. PubMed ID: 27025835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
    Jacobson IM; Lawitz E; Gane EJ; Willems BE; Ruane PJ; Nahass RG; Borgia SM; Shafran SD; Workowski KA; Pearlman B; Hyland RH; Stamm LM; Svarovskaia E; Dvory-Sobol H; Zhu Y; Subramanian GM; Brainard DM; McHutchison JG; Bräu N; Berg T; Agarwal K; Bhandari BR; Davis M; Feld JJ; Dore GJ; Stedman CAM; Thompson AJ; Asselah T; Roberts SK; Foster GR
    Gastroenterology; 2017 Jul; 153(1):113-122. PubMed ID: 28390869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
    Cheng PN; Chiu YC; Chien SC; Chiu HC
    J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.
    Cordie A; Elsharkawy A; Abdel Alem S; Meshaal S; El Akel W; Abdellatif Z; Kamal W; Al Askalany M; Kamel S; Abdel Aziz H; Kandeel A; Esmat G
    Trans R Soc Trop Med Hyg; 2020 Apr; 114(4):232-240. PubMed ID: 31925434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
    Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.
    Mangia A; Arleo A; Copetti M; Miscio M; Piazzolla V; Santoro R; Squillante MM
    Liver Int; 2016 Jul; 36(7):971-6. PubMed ID: 26786792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.